Final Logo-01.png
CBD Nutraceuticals Market is estimated to Reach USD 17.9 Billion by 2034, with a 16.40% CAGR and Meeting Growing Wellness Demands - By PMI
27 févr. 2024 17h30 HE | PMI
Covina, Feb. 27, 2024 (GLOBE NEWSWIRE) -- “According to the recent research study, the CBD Nutraceuticals Market size was valued at about USD 4.5 Billion in 2024 and expected to grow at CAGR of...
CV_Sciences_logo2021.png
CV Sciences, Inc. Reports Second Quarter 2021 Financial Results
12 août 2021 16h05 HE | CV Sciences, Inc.
SAN DIEGO, Aug. 12, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD)...
CV_Sciences_logo2021.png
CV Sciences, Inc. to Announce Second Quarter 2021 Results on August 12, 2021
05 août 2021 08h00 HE | CV Sciences, Inc.
SAN DIEGO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD)...
CV_Sciences_Logo_black_tm.jpg
CV Sciences, Inc. to Announce Fiscal Year and Fourth Quarter 2020 Results on March 18, 2021
10 mars 2021 07h00 HE | CV Sciences, Inc.
SAN DIEGO, March 10, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD)...
CV_Sciences_Logo_black_tm.jpg
CV Sciences, Inc. Announces Closing of Committed Equity Financing Transaction
08 déc. 2020 07h00 HE | CV Sciences, Inc.
SAN DIEGO, Dec. 08, 2020 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD)...
CV_Sciences_Logo_black_tm.jpg
CV Sciences, Inc. Reports Second Quarter 2020 Financial Results
06 août 2020 16h05 HE | CV Sciences, Inc.
SAN DIEGO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD)...
CV™ Acute 07282020
CV Sciences, Inc. Announces Expansion with the Launch of CV™ Acute and New Immunity Product Line
29 juil. 2020 08h00 HE | CV Sciences, Inc.
SAN DIEGO, July 29, 2020 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent leader in hemp derived cannabidiol (CBD) products, today...
CV_Sciences_Logo_black_tm.jpg
CV Sciences, Inc. Announces Plan to Adjourn Annual Meeting of Stockholders to June 16, 2020
20 mai 2020 16h30 HE | CV Sciences, Inc.
SAN DIEGO, May 20, 2020 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today...
CV_Sciences_Logo_black_tm.jpg
CV Sciences, Inc. Receives Formal Notice of Patent Issuance from USPTO for Proprietary Cannabidiol (CBD) and Nicotine Formulation for Treating Smokeless Tobacco Addiction
20 mai 2020 08h00 HE | CV Sciences, Inc.
SAN DIEGO, May 20, 2020 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD)...
CV_Sciences_Logo_black_tm.jpg
CV Sciences, Inc. to Announce First Quarter 2019 Results on May 8, 2020
30 avr. 2020 16h05 HE | CV Sciences, Inc.
SAN DIEGO, April 30, 2020 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD)...